Background: Glanzmann Thrombasthenia (GT) is a rare inherited genetic platelet disorder characterized
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Introduction:
Platelets have many roles in physiological processes in the human body, including hemostasis. In which adhesive proteins such as collagen and thromboplastin are released by damaged endothelium, which binds and aggregate platelets leading to thrombus formation with subsequent activation of coagulation pathways. Any disruption of this pathway acquired or inherited, will result in bleeding.
Glanzmann Thrombasthenia (GT), which was known as Hereditary Hemorrhagic Thrombasthenia, is a rare autosomal recessive disorder of GPIIb/IIIa surface receptor that was first described in 1918. The exact number of affected cases is unknown, but it is estimated that one in a million have GT, with women being affected more than men, 60% to 40% respectively. GT, was noticed to be more common in certain ethnic groups such as Arabs and French gypsies Type 1: > 5% of normal GPIIb/IIIa levels (severe).
Type 2: 10-20% of normal GPIIb/IIIa levels (Moderate).
Type 3: Normal GPIIb/IIIa levels, but functionally inactive (Variant).
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The Case:
A 19 years old Arab descent female presented to the emergency department with severe menorrhagia with generalized fatigue for ten days. The patient denied any bleeding in between cycles but complained from frequent epistaxis, an initial diagnosis of von Willebrand disease was made but ruled out soon after due to normal coagulation parameters. On examination a pale, ill-looking female with signs of anemia including conjunctival pallor and tachycardia.
Patient was admitted to female medical ward and initial lab results showed RBCs: 1.70X1012/L, Hb 4.20 g/dL, Hct 14.40%, MCV 84.50fL, MCH 24.70 pg, MCHC 29.30g/dL, RDW 21.60%. Platelets 156.00 x103/mcL, and normal coagulation profile, with prolonged bleeding time. A thorough history was taken from the patient that revealed that the patient went for gynaecology clinic three years ago with complaint of late menarche, similar issue was noted in the family, and had an extensive hormonal and biomedical examination, all of which came out negative for a cause of late menarche also history revealed a multiple previous episodes of epistaxis that was controlled by simple measures such as nasal compression, a positive family history of GT was noted, Flow-cytometry was done which showed decreased levels of CD41 and CD61. Thus, diagnosis of GT was made. The patient was treated with a blood transfusion and then discharged.
Discussion:
Glanzmann Thrombasthenia diagnosis of is often challenging and overlooked. GT, shares many clinical and laboratory finding with other more common acquired bleeding disorders. GT, should be considered as a differential diagnosis in patients with a history of severe bleeding flowing minor trauma or unprovoked bleeding. The family history of consanguinity or for other affected members, such as in this case, plays a fundamental role in GT, diagnosis.
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The majority of GT, affected patients will be diagnosed in the first five years of their lives due to recurring gingival bleeding or epistaxis as the most common presentations i . In males, excessive bleeding after circumcision has been reported as the first sign of the disease. However, females could be diagnosed later in life when menses ensue. Although fatal bleeding can happen to both genders at any stage in life, it usually tends to decrease in incidence as patients age The early workup with GT patients lead to the discovery of some of the currently known potent antithrombotics, when a patient with GT who developed a unique powerful antibody against GPIIb/IIIa following multiple transfusions appeared to be a potential source of a therapeutic agent. This antibody was used as ait was used to make a murine humanized monoclonal antibody, (abciximab) was introduced into clinical practice showing significant reduction in the combined endpoint of acute myocardial infarction, need for emergency coronary artery bypass grafting and mortality in patients undergoing percutaneous coronary intervention vii .
TAKE HOME POINTS:
1. Suspicion of Glanzmann Thrombasthenia should be raised in cases of family bleeding after a minor trauma in males and females.
2. Patient education is a cornerstone in the management of Glanzmann Thrombasthenia as bleeding episodes can occur at any time.
